Worth reading
38Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
26337359151
Yen (total transfer consideration)Wording
Definitive
How definitive the wording is.This transaction
Share TransfersCounterpartyNipro Vascular Co., Ltd.
Disclosing companyNIPRO CORPORATION
TimelineThe spacing between the points is proportional to the actual number of days.
Target company
Development and manufacture of intravascular imaging medical devices, Holding Company
Location 142 North Road, Suite G, Sudbury, MA, 01776 USA, 142 North Road, Suite G, Sudbury, MA, 01776 USAShare capital Gentuity, LLC：143,445,859.70USD, Spryte Medical Holdings, LLC：85,000,000USDDate of incorporation Gentuity, LLC: 14 October 2013, Spryte Medical Holdings, LLC: 13 March 2023
Net SalesGentuity, LLC: ¥523 million (fiscal year ended December 2025), Spryte Medical Holdings, LLC: ¥0 million (fiscal year ended December 2025)
Operating profitGentuity, LLC: operating loss of ¥4,660 million (fiscal year ended December 2025), Spryte Medical Holdings, LLC: operating loss of ¥2,859 million (fiscal year ended December 2025, consolidated)
Net income for the current fiscal yearGentuity, LLC: net loss of ¥4,616 million (fiscal year ended December 2025), Spryte Medical Holdings, LLC: net loss attributable to owners of the parent of ¥2,810 million (fiscal year ended December 2025, consolidated)
Net assetsGentuity, LLC: net assets of negative ¥3,853 million (fiscal year ended December 2025), Spryte Medical Holdings, LLC: net assets of negative ¥270 million (fiscal year ended December 2025, consolidated)
Consideration and expenses
Acquisition priceGentuity, LLC: ¥21,347,784,351, Spryte Medical Holdings, LLC: ¥4,989,574,800
Impact on Business Performance
This is a business reorganization within the Company’s group and will have no impact on consolidated results.
| Item | Details |
|---|---|
| Transaction name | Share Transfers |
| Counterparty name | Nipro Vascular Co., Ltd. |
| Name of the Subject Company | Gentuity, LLC, Spryte Medical Holdings, LLC |
| Business Description of the Subject Company | Development and manufacture of intravascular imaging medical devices, Holding Company |
| Location of the Subject Company | 142 North Road, Suite G, Sudbury, MA, 01776 USA, 142 North Road, Suite G, Sudbury, MA, 01776 USA |
| Capital Stock of the Subject Company | Gentuity, LLC：143,445,859.70USD, Spryte Medical Holdings, LLC：85,000,000USD |
| Date of Establishment of the Subject Company | Gentuity, LLC: 14 October 2013, Spryte Medical Holdings, LLC: 13 March 2023 |
| Net Sales of the Subject Company | Gentuity, LLC: ¥523 million (fiscal year ended December 2025), Spryte Medical Holdings, LLC: ¥0 million (fiscal year ended December 2025) |
| Operating Profit of the Subject Company | Gentuity, LLC: operating loss of ¥4,660 million (fiscal year ended December 2025), Spryte Medical Holdings, LLC: operating loss of ¥2,859 million (fiscal year ended December 2025, consolidated) |
| Net Income of the Subject Company | Gentuity, LLC: net loss of ¥4,616 million (fiscal year ended December 2025), Spryte Medical Holdings, LLC: net loss attributable to owners of the parent of ¥2,810 million (fiscal year ended December 2025, consolidated) |
| Net Assets of the Subject Company | Gentuity, LLC: net assets of negative ¥3,853 million (fiscal year ended December 2025), Spryte Medical Holdings, LLC: net assets of negative ¥270 million (fiscal year ended December 2025, consolidated) |
| Acquisition price | Gentuity, LLC: ¥21,347,784,351, Spryte Medical Holdings, LLC: ¥4,989,574,800 |
| Number of shares acquired | Gentuity, LLC: 103,417,476 shares; number of voting rights: Not disclosed, Spryte Medical Holdings, LLC: 78,660,000 shares; number of voting rights: Not disclosed |
| Voting rights ownership percentage | Gentuity, LLC 78％ → 0％ / Spryte Medical Holdings, LLC 39％ → 0％ |
| Impact on Business Performance | This is a business reorganization within the Company’s group and will have no impact on consolidated results. |
| Date of board resolution | 26 June 2026 |
| Execution Date / Effective Date | 30 June 2026 (scheduled) |
Items this document does not state (15)
Expenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Contract DateValuation methodologyIndependent valuation institutionSpecial CommitteeConditions Precedent to ExecutionManagement structure after acquisition
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.As part of an organizational restructuring to operate the vascular business as an integrated, end-to-end business, the shares will be transferred to Nipro Vascular Co., Ltd., which oversees the business.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.